Your finished product, with the evidence it needs
A cosmetic reaches the market twice: when it passes the safety assessment, and when it convinces the people who have to sell it. We work on both fronts — the dossier and the narrative — with in vitro tests on reconstructed human models, no animal testing.
Let’s talk about your productThree situations, three ways to set up the work
Clients almost never come asking for a test: they come with a decision to make. The test comes after.
You are about to launch a reference
You need the safety package for the dossier and at least one solid piece of evidence behind the main promise. Here the critical variable is time, and it is won by choosing the tests well rather than running many of them.
You have a catalogue product to strengthen
It works, but it does not stand out. Comparative studies against category references, and efficacy evidence on the finished product, put it back in the game in front of the buyer.
You have to choose between two formulations
In vitro screening before the pilot batch costs a fraction of an industrial trial and settles the internal discussion with data instead of opinion.
A claim is the pact you make with whoever buys from you
Regulation 1223/2009 requires every label statement to be backed by documented evidence, and controls on this point have grown stricter. The buyer, for their part, asks to see the data before listening to the story.
A promise without evidence is not a weak claim: it is a claim that cannot be made.
What we do
Two families of tests which, in real projects, almost always travel together.
Safety — for the dossier
- In vitro skin irritation on reconstructed epidermis (OECD TG 439)
- Eye irritation on reconstructed corneal epithelium (OECD TG 492)
- Short Time Exposure for eye irritation (OECD TG 491)
- In vitro skin corrosion (OECD TG 431)
- MTT and NRU cytotoxicity on cell cultures and reconstructed tissues
- In vitro 3T3 NRU phototoxicity
- In vitro assessment of pro-sensitising potential, with preliminary screening
- Challenge test UNI EN ISO 11930 and microbial count
- Stability and shelf life
Efficacy — for the promise
- Soothing power and anti-inflammatory potential on the district
- Antioxidant capacity by the TEAC method and complementary techniques
- Prebiotic activity and skin microbiome rebalancing
- Antimicrobial and anti-biofilm activity, on a broad strain collection
- Antiviral activity following official methods
- Anti-glycation, with AGE fluorescence measurement
- Hydration, barrier effect and regeneration on 3D reconstructed skin
- Comparative studies against reference products
- qPCR and metagenomics on swabs from your in vivo studies
How a project runs
Four steps, always the same, because it is the first one that decides whether the final data will be useful.
What if the problem is the active?
When the promise does not hold because the right ingredient is missing, we do not stop at the report: three biotech actives are developed and produced by us, with the evidence dossier already built.
Lactive™
Bioactivated lactoferrin releasing synergistic peptides: it acts selectively on skin pathogens, disrupts biofilm and triggers regeneration.
Evobiom™
A postbiotic from L. rhamnosus for rebalancing the skin microbiome, supporting the recovery of sensitive, reactive skin.
ExoLife Rh™
Extracellular vesicles from L. rhamnosus obtained by precision fermentation: microcirculation, barrier resilience, radiance.
Tell us what your product has to demonstrate.
From the claim you have in mind we get to the test plan in a conversation, not in a price list.
Contact us